The stock of Novo Nordisk A/S (NYSE:NVO) decreased by -$1.13 on Wednesday to $189.24, down -0.59 percent. The last five days have seen an average of 1,323,551 shares of common stock traded. 28 times new highs were reached in the current year, with a gain of $53.74. The average number of shares traded over the last 20 days was 2,081,113, while the average volume over the last 50 days totaled 1,549,303.
NVO stock appreciated 17.01% since last month. On 08/04/23, the company’s shares reached a one-month low of $156.39. The stock touched a high of $192.18 on 08/08/23, after rallying from a low of $95.02 in 52 weeks. The price of NVO stock has risen by 39.83% or $53.74 this year, reaching a new high 28 times. Still, the stock price is down -1.53% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Novo Nordisk A/S (NVO) has a trailing price-to-earnings (P/E) ratio of 43.99. Beta for the stock is 0.43. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 11.24, the price-to-book (PB) ratio of 32.40.
Company paid $0.8836 per share in dividends, a decrease of -25.67% from $1.1887 last year. A $0.3052 dividend decrease was reported on Thursday August 10 2023.
Financial Health
For the three months ended March 30, Novo Nordisk A/S’s quick ratio was 0.70, while its current ratio was 0.90, indicating its inability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending March 30 is 0.21, and the total debt to equity ratio is 0.28. As far as profitability goes, gross margin for the trailing twelve months is 84.40% percent. Novo Nordisk A/S’s EBITDA margin for the year ended March 30 was 45.79%, whereas its operating margin stood at 42.80% for the same period. Based on annual data, it had gross profit of $21.03 billion and revenue of $25.06 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. NVO’s return on assets (ROA) during the last 12 months has been 26.50%. There was a 56.10% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 81.40%.
Earnings Surprise
According to Novo Nordisk A/S’s quarterly financial report for the quarter that ended March 30. A higher net income was reported in the quarter under review than the previous quarter. It was predicted that Novo Nordisk A/S’s quarterly earnings would be $1.29, but it ended up being $1.27, beating the consensus by 1.60%. EBITDA was $3.81 billion for the quarter. At the end of Novo Nordisk A/S’s most recent quarter ended March 30, its liabilities totaled 27.8 billion, while its total debt was $25.7 billion.
Technical Picture
Here’s a quick look at Novo Nordisk A/S’s (NVO) price momentum from a technical perspective. As of 29 August, the RSI 9-day stood at 64.36%, suggesting the stock is Neutral, with a 23.24% historical volatility rate.
The stochastic %K and %D were 81.54% and 74.06% respectively, while the average true range (ATR) was 3.86. Based on the 14-day stochastic reading of 82.35%, the RSI (14) reading is 64.45%. On the 9-day MACD Oscillator, the stock is at 2.00, and the 14-day reading is at 3.39.
Analyst Ratings
In its analyst report released on July 14, 2023, HSBC Securities began covering Novo Nordisk A/S (NYSE: NVO). The stock was rated as a Buy by the brokerage firm. Analysts have assigned Novo Nordisk A/S (NVO) an Overweight rating. NVO is a stock that is recommended for selling by 3 brokerage firms, while 7 companies recommend holding. The stock is underweighted by 1 analyst. Among the analysts who rate the stock, 1 rate it overweight and 14 others recommend it as a buy.
What is NVO’s price target for the next 12 months?
The current consensus forecast for the stock is between $105.39 and $225.49, with a median target price of $192.21. In analyzing these forecasts, the average price target given by analysts for Novo Nordisk A/S (NVO) is $185.44.
